Lablabo creates pack for HRT treatment

Published: 24-Jan-2011
Drug Delivery Pharmaceutical

Uses an airless metering dispenser with EasyFoil aluminium pouch

Lablabo creates pack for HRT treatment
Lablabo of France has developed a high-performance airless pack for Azur Pharma’s Elestrin hormonal replacement therapy, which has been launched in the US following approval by the US Food and Drug Administration.

Lablabo’s pack consists of a Sillage airless metering dispenser with an EasyFoil aluminium pouch.

Made of an aluminium and polyethylen multilayer foil, this new pouch is said to ensure maximum protection of the product inside against oxygen and UV rays. Its cylindrical shape guarantees high restitution rates (up to 98% of the product delivered) and easy filling with basic equipment, the firm says.

The metering pump delivers a constant and precise dose of 0.92ml.

The Elestrin sales pack used by the Irish pharmaceutical firm includes two 38ml Sillage airless metering dispensers for a two-month treatment.

Lablabo, based in Annemasse, says it has Drug Master Files (DMFs) registered with the FDA for all of it products and received ISO 15378 certification last December.

See more

You may also like

Regulatory
Early phase analytical strategy for biosimilars in a shifting regulatory landscape

Early phase analytical strategy for biosimilars in a shifting regulatory landscape

Read more
As FDA and EMA guidance continues to reinforce analytical comparability as the foundation of biosimilar development, investing in comprehensive early-stage characterisation is becoming essential to reduce uncertainty and improve development outcomes, says Dr Andrew J. Reason, CEO at BioPharmaSpec

Trending Articles

  1. Kindeva appoints Brok Weichbrodt as Chief Transformation Officer to accelerate growth strategy and commercial excellence Kindeva, a global drug delivery Contract Development and Manufacturing Organization (CDMO), today announced the appointment of Brok Weichbrodt as Chief Transformation Officer to strengthen operational excellence, scale execution, and accelerate growth as the company enters the next phase of its value creation plan
  2. Entact Bio appoints John G. Houston, Ph.D., to its Board of Directors A veteran biopharma innovator who helped advance the first FDA-approved PROTAC drug, Dr. Houston will strengthen Entact's leadership in induced-proximity therapeutics
  3. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence
  4. Alzheimer’s Association launches $100m trial combining lifestyle changes and GLP-1s to prevent cognitive decline The global study builds on US POINTER trial findings, testing whether adding a metabolism-targeting drug to structured lifestyle programmes can further reduce cognitive decline risk in at-risk older adults during a three-year period

Upcoming event

CPhI Milan

6–8 October 2026 | Exhibition | Fiera Milano, Italy See all

You may also like

Regulatory
Early phase analytical strategy for biosimilars in a shifting regulatory landscape

Early phase analytical strategy for biosimilars in a shifting regulatory landscape

As FDA and EMA guidance continues to reinforce analytical comparability as the foundation of biosimilar development, investing in comprehensive early-stage characterisation is becoming essential to reduce uncertainty and improve development outcomes, says Dr Andrew J. Reason, CEO at BioPharmaSpec
Manufacturing
ten23 health expands excipient options for biologic drug development with an external collaboration

ten23 health expands excipient options for biologic drug development with an external collaboration

ten23 health today highlights its research collaboration with dsm-firmenich, focused on expanding excipient options for parenteral biologic drug products
Drug Delivery
EpilepsyGTx selects ClearPoint Neuro technology for Phase I/IIa epilepsy gene therapy trial

EpilepsyGTx selects ClearPoint Neuro technology for Phase I/IIa epilepsy gene therapy trial

The partnership will support MRI-guided delivery of investigational gene therapy EPY201 in first-in-human trials targeting focal refractory epilepsy, where precision administration is "key to efficacy and safety"
Pharmaceutical
Formulation freedom in clinical development: Why Fill2Weight matters

Formulation freedom in clinical development: Why Fill2Weight matters

As drug discovery accelerates, especially for poorly soluble small‑molecule compounds, formulation teams increasingly modify particle size, morphology and structure to improve dissolution in the body. This is precisely where 3P innovation’s proprietary Fill2Weight Gravimetric Powder Filler becomes a game‑changer
Media
Plan your marketing strategy with Manufacturing Chemist

Plan your marketing strategy with Manufacturing Chemist

Discover upcoming special reports, themed features and commercial opportunities to help you connect with pharmaceutical manufacturing decision-makers throughout the year
Research & Development
Alzheimer’s Association launches $100m trial combining lifestyle changes and GLP-1s to prevent cognitive decline

Alzheimer’s Association launches $100m trial combining lifestyle changes and GLP-1s to prevent cognitive decline

The global study builds on US POINTER trial findings, testing whether adding a metabolism-targeting drug to structured lifestyle programmes can further reduce cognitive decline risk in at-risk older adults during a three-year period
Pharmaceutical
Teva and Polpharma Biologics sign global licensing deal for Ocrevus biosimilar candidate

Teva and Polpharma Biologics sign global licensing deal for Ocrevus biosimilar candidate

The agreement will expand Teva’s biosimilars pipeline, with the company securing exclusive commercialisation rights for Polpharma Biologics’ proposed ocrelizumab biosimilar across key global markets
Subscribe now